Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Galsky

Showing results (31-40 of 389) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Understanding Adjuvant Therapy for Upper Tract Urothelial CarcinomaStephanie A Berg, Matthew D Galsky
Expert Review of Anticancer Therapy|February 27, 2025
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinomaEric J Miller, Matthew D Galsky
Clinical Advances in Hematology & Oncology : H&O|April 20, 2013
Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approachesMatthew D Galsky, Josep Domingo-Domenech
The Lancet. Oncology|June 8, 2013
Tumour angiogenesis: an elusive target in castration-resistant prostate cancerMatthew D Galsky, William K Oh
European Urology|September 16, 2014
Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?Benjamin A Gartrell, Matthew D Galsky
European Urology|July 9, 2026
Rethinking Perioperative Strategies in Clinically Node-positive Upper Tract Urothelial Carcinoma in the KEYNOTE-B15 EraPierre-Etienne Gabriel, Matthew D Galsky
Expert Opinion on Emerging Drugs|June 6, 2025
The role of HER2-targeted therapy in urothelial carcinomasJeanny B Aragon-Ching, Matthew D Galsky
The New England Journal of Medicine|October 31, 2007
Germ-cell tumorsVaruni Kondagunta, Matthew D Galsky, Guru Sonpavde
Cancer Treatment Reviews|March 18, 2014
Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trialsTomohiro Funakoshi, Asma Latif, Matthew D Galsky
Cancer|March 8, 2021
The impact of the globalization of cancer clinical trials on the enrollment of Black patientsSerena Tharakan, Xiaobo Zhong, Matthew D Galsky
Pageof 39

Showing results (31-40 of 389) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Understanding Adjuvant Therapy for Upper Tract Urothelial CarcinomaStephanie A Berg, Matthew D Galsky
Expert Review of Anticancer Therapy|February 27, 2025
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinomaEric J Miller, Matthew D Galsky
Clinical Advances in Hematology & Oncology : H&O|April 20, 2013
Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approachesMatthew D Galsky, Josep Domingo-Domenech
The Lancet. Oncology|June 8, 2013
Tumour angiogenesis: an elusive target in castration-resistant prostate cancerMatthew D Galsky, William K Oh
European Urology|September 16, 2014
Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?Benjamin A Gartrell, Matthew D Galsky
European Urology|July 9, 2026
Rethinking Perioperative Strategies in Clinically Node-positive Upper Tract Urothelial Carcinoma in the KEYNOTE-B15 EraPierre-Etienne Gabriel, Matthew D Galsky
Expert Opinion on Emerging Drugs|June 6, 2025
The role of HER2-targeted therapy in urothelial carcinomasJeanny B Aragon-Ching, Matthew D Galsky
The New England Journal of Medicine|October 31, 2007
Germ-cell tumorsVaruni Kondagunta, Matthew D Galsky, Guru Sonpavde
Cancer Treatment Reviews|March 18, 2014
Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trialsTomohiro Funakoshi, Asma Latif, Matthew D Galsky
Cancer|March 8, 2021
The impact of the globalization of cancer clinical trials on the enrollment of Black patientsSerena Tharakan, Xiaobo Zhong, Matthew D Galsky
Pageof 39